Mutations in the GBA gene that encodes glucocerebrosidase cause the lysosomal storage disorder Gaucher disease but also increase the risk for Parkinson's disease. Mazzulli et al. (2011) uncover a possible mechanism to explain this connection: loss of glucocerebrosidase creates a positive feedback loop of reduced lysosomal function and a-synuclein accumulation, ultimately leading to neurodegeneration.
Genetics has taught us a great deal about disorders in which the underlying cause is complex and, thus, often relegated to the catch all ''sporadic'' diseases. However, the gap between identifying genes and understanding their pathogenic pathways remains enormous. In this context, the new study by Mazzulli et al. (2011) in the current issue of Cell uncovers a tractable biochemical relationship between two complex diseases, the neurodegenerative disorder Parkinson's disease and the lysosomal disorder Gaucher disease, in which lipids accumulate in central organs.
Parkinson's disease is characterized by two pathological features. First, neurons die in regions of the brain, which control the normal fluidity of movement. This leads to the clinical picture of tremor, stiffness, slowness, and difficulties with posture. Second, proteins and lipids accumulate into structures, called Lewy bodies, inside surviving neurons (Gai et al., 2000) . The synaptic protein a-synuclein is one key component of Lewy bodies, and variations in its gene, SNCA, are associated with inherited and sporadic Parkinson's disease (Hardy, 2010) . When present in Lewy bodies, a-synuclein is aggregated; however, it is unclear which species causes cell death, the aggregated form or some intermediate in the aggregation pathway, such as soluble oligomers.
Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, which encodes the enzyme glucocerebrosidase (GCase). Parents and grandparents of patients with Gaucher disease have unusually high rates of Parkinson's disease, suggesting that these mutations are risk factors for Parkinson's disease (Velayati et al., 2010) . Although mutations underlying Gaucher disease are loss of function, patients with Parkinson's disease always carry one wild-type GBA allele and thus possess at least 50% of normal enzyme function. Furthermore, there is no obvious correlation between the type of GBA mutation (i.e., completely inactive or one with some residual enzyme activity) and the risk of Parkinson's disease (Velayati et al., 2010) . Thus, the genetic mechanism by which GBA mutations promote Parkinson's disease is still not clear.
GCase catalyzes the conversion of glucocerebroside to glucose and ceramide inside the lysosome. One possible link between GCase function and Parkinson's disease risk is a-synuclein. The main degradation pathway of a-synuclein is via lysosomal processing, and GCase interacts with a-synuclein in acidic environments, such as the lumen of the lysosome (Yap et al., 2011) . Interestingly, a-synuclein has been shown to inhibit vesicle transport between the endoplasmic reticulum (ER) and the Golgi apparatus, the main trafficking route for GCase to reach the lysosome. Thus, increased expression of a-synuclein should decrease levels of GCase in lysosomes. As an aside, mutant a-synuclein can inhibit chaperone-mediated autophagy, a process by which some substrates are imported into and degraded by the lysosome (Cuervo et al., 2004) . Therefore, lysosomal dysfunction could increase a-synuclein levels, and a-synuclein could inhibit lysosomal function in multiple ways.
Indeed, the central idea in the paper by Mazzulli et al. is that this exact type of positive feedback loop occurs in Parkinson's disease patients carrying GBA mutations. To model the loss of enzyme function seen in these patients, the authors decrease the expression of GBA in mouse neurons to 50% of control conditions. Over a few days in culture, the neurons loose lysosomal turnover of long-lived proteins, including a-synuclein. The author observe this phenotype in primary neurons and in neurons reprogrammed from induced pluripotent stem cells (iPSCs), with the latter having both copies of GBA mutated, as found in neurons from patients with Gaucher disease.
The authors then characterize the formation of a-synuclein oligomers in cells, in mice, and in brains from people who had mutations in GBA. Soluble oligomers are found in neuronopathic forms of Gaucher disease, as well as Parkinson's disease patients heterozygous for GBA mutations. This observation suggests that the emergence of oligomers is not correlated with Lewy bodies but rather is a more fundamental consequence of GBA mutations. Mazzulli and colleagues also show that expression of a-synuclein impacts the trafficking of GCase from the ER-golgi to the lysosome, indicating that a-synuclein affects lysosomes irrespective of the presence of GBA mutations.
Simplistically, the data by Mazzulli and colleagues suggest the following model: a rise in a-synuclein levels through mutation, response to stress, or neuronal maturation (Li et al., 2004 ) inhibits the normal negative feedback loop of degradation by the lysosome, leading to more a-synuclein and more inhibition ( Figure 1A ). Then the system would transition from one stable state to a second one that is self-sustaining, unless another pathway intervenes to stop it.
Clearly, these are important results and conclusions for research on Gaucher disease and Parkinson's disease. If pathogenesis is driven by positive feedback that triggers disease when it rises above a given threshold ( Figure 1B ), then we may now have a simple model that explains a number of peculiarities of neurodegeneration. First, homeostatic processes that keep the feedback loops in check may fail with time, leading to the age association observed for neurodegeneration. These models also postulate that stochastic events, such as random fluctuations in the levels of a-synuclein, should contribute as strongly to pathogenesis as genetic or environmental factors. Finally, if the process is feedforward, then it should be possible to intervene in either portion of the cycle and limit toxicity.
The hypothesis by Mazzulli and colleagues also leads to a few testable predictions. For example, removing a-synuclein from models of Gaucher disease should limit neurodegeneration. Equally, raising GCase activity in sporadic Parkinson's disease should be beneficial.
Either intervention would prevent the pathogenic effects of the other protein, and there should be directionality.
Replicating some aspects of these new findings will be challenging because, as for many rare neurodegenerative disorders, it will be hard to find autopsied cases for this purpose. Interestingly, another recent study, which used different approaches to fractionate proteins in brain than Mazzulli and colleagues, examined a-synuclein solubility in Gaucher brains with and without Lewy bodies and came to somewhat different conclusions (Choi et al., 2011) . The experiments on mouse and primary cell presented by Mazzulli et al. should be easier to replicate, and different strategies for achieving enzymatic deficiency may prove informative.
A major question that remains is whether the acute experiments (i.e., days-weeks) presented by Mazzulli and colleagues extrapolate to a very chronic (i.e., >50 years) human disease. This is a challenge for many studies on neurodegeneration; laboratory experiments are required to examine interventions, but the real human diseases are dramatically more complex and longer term. There is a huge amount of literature demonstrating that oligomeric assemblies of proteins are toxic in various models of neurodegeneration. However, many of these studies rely on correlative measures, and the current literature does not disprove the alternate hypothesis that higher levels of monomeric a-synuclein are causal for pathogenesis. This is mainly because tools for removing oligomers, while keeping monomers, are not well advanced. It would be fascinating to see how the disease might respond if one species could be selectively removed.
Human genetics should also be taken into account. Common variants around the SNCA locus are associated with sporadic Parkinson's disease, perhaps due to increased expression of a-synuclein (Hardy, 2010) . It would be interesting to determine quantitatively how much additional risk arises when both GBA variants and SNCA risk alleles are present. The positive feedback loop model ( Figure 1A) suggests that the effect of the allele combination on lifetime risk would be more than additive, but that once a-synuclein protein levels reach the pathogenic threshold ( Figure 1B) , then the increased risk would be minimal. Levels of a-synuclein are narrowly tuned in the human brain because triplication alleles, which are associated only with a 2-fold increase in protein expression (Singleton et al., 2003) , lead to a very aggressive form of Parkinson's disease (Gwinn et al., 2011) . Presumably, once this threshold is reached, additional risk would be minimal.
Some of these ideas are more easily tested than others, but as is often true for first-rate science, the study by Mazzulli and colleagues leads to several new avenues that can, and should, be tested (GCase) is also imported into the lysosome after the enzyme matures through the ER-Golgi pathway. In pathogenic situations, accumulation of a-synuclein may block ER-Golgi transport, leading to the loss of GCase in the lysosome. This amplifies the effects by limiting degradation of a-synuclein, causing further accumulation of the protein and possibly other detrimental effects on the lysosome. (B) If this series of positive feedback loops (small circles with arrows) continues over time, then a-synuclein levels will tend to increase with age. Presumably, at a certain point, a-synuclein levels will exceed a pathogenic threshold (arbitrarily indicated by a red line) and be associated with disease.
by others. In my opinion, the central conclusion from this study is the positive feedback loop between a-synuclein accumulation and GCase dysfunction; obtaining data to support or refute this idea will be key to the progress of understanding why GBA mutations influence the risk of Parkinson's disease in the next few years.
